GlassScriptPhysician profile
Sikarin Upala
NPI 1013334556
$11,114.70
in general payments reported to CMS, 2019-2025
44 companies · $833 in 2025
The $833 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $460 · 2020: $2,572 · 2021: $2,248 · 2022: $2,368 · 2023: $262 · 2024: $2,372 · 2025: $833.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,432 · Travel and Lodging: $970 · Education: $64.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,432.49 |
| Travel and Lodging | $969.78 |
| Education | $64.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,679.04 | 2021-2025 | Minimed 780g |
| Novo Nordisk INC | $1,633.11 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Medtronic Minimed, INC. | $1,381.07 | 2019-2020 | |
| Insulet Corporation | $658.82 | 2020-2022 | |
| Dexcom, INC. | $606.60 | 2020-2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $596.59 | 2019-2024 | Airsupra |
| Amgen INC. | $539.88 | 2019-2025 | Tepezza |
| Lilly USA, LLC | $423.78 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbott Laboratories | $358.75 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $317.83 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $317.22 | 2021-2025 | |
| Corcept Therapeutics | $302.04 | 2020-2025 | Korlym |
| Genzyme Corporation | $300.00 | 2020 | |
| Xeris Pharmaceuticals, INC. | $287.54 | 2020-2025 | Gvoke Hypopen, Recorlev |
| Otsuka America Pharmaceutical, INC. | $179.84 | 2020-2022 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sikarin Upala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.